Evogene EBIT

The latest EBIT for EVGN.TA is $-21M as of June 2026. That compares with $-14M in the prior-year period — down 52.8% year over year. That is below the Materials sector average of $140B. Investors often review this figure alongside Evogene's historical trend and sector peers before judging valuation or financial health.

Over the past year, EVGN.TA's EBIT moved from $-14M to $-21M — a 52.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Evogene's operating scale or balance-sheet position.

Against Materials companies, EVGN.TA currently prints $-21M for EBIT, while the sector average sits near $140B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Evogene's growth, margins, and balance sheet.

A EBIT figure of $-21M for EVGN.TA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Materials average is about $140B. Explore the charts below for those layers of context.

After noting EVGN.TA's EBIT ($-21M), review year-over-year change from $-14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.